STOCK TITAN

Rosalind funds disclose 9.2% InspireMD (NSPR) stake with warrant blocker

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

InspireMD, Inc. (NSPR) received an updated ownership report from Rosalind-related investors on an amended Schedule 13G as of 12/31/2025. Rosalind Advisors, Inc., Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P., and portfolio managers Steven Salamon and Gilad Aharon collectively report beneficial ownership of 3,905,743 common shares, or 9.2% of InspireMD’s common stock, based on 42,370,995 shares outstanding as of November 10, 2025.

The group also holds 7,081,361 common shares issuable upon exercise of pre-funded and standard warrants, but these cannot currently be exercised because of a 9.99% “blocker” that prevents exercises which would push holdings above that level. The reporting persons state that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of InspireMD.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth in Row 11 of the cover page for each Reporting Person is based upon 42,370,995 shares of common stock outstanding of the Issuer as of November 10, 2025, in accordance with the 10Q filed on November 10th. However, as more fully described in Item 4, the securities reported in rows 6, 8, and 9 show the number of shares of Common Stock that would be issuable upon exercise of such reported securities and do not give effect to blocker provisions. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows 6, 8, and 9. (6) 3,905,743 shares of Common Stock 7,081,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)3,905,743 shares of Common Stock 7,081,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)3,905,743 shares of Common Stock 7,081,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)3,508,336 shares of Common Stock 5,977,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)397,407 shares of Common Stock 1,104,000 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Rosalind Advisors, Inc.
Signature:Steven Salamon
Name/Title:President
Date:02/11/2026
SALAMON STEVEN A J
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:02/11/2026
Aharon Gil
Signature:GIl Aharon
Name/Title:Gil Aharon
Date:02/11/2026
Rosalind Master Fund L.P.
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:02/11/2026
Rosalind Opportunities Fund I L.P.
Signature:Steven Salamon
Name/Title:Director, Rosalind Opportunities Fund I GP. Inc. (as General Partners to Rosalind Opportunities Fund I)
Date:02/11/2026

FAQ

What stake in InspireMD (NSPR) do the Rosalind entities report?

Rosalind-related investors report beneficial ownership of 3,905,743 InspireMD common shares, or 9.2% of the company. This percentage is calculated using 42,370,995 common shares outstanding as of November 10, 2025, as disclosed in InspireMD’s Form 10-Q.

Who are the reporting persons in this InspireMD (NSPR) Schedule 13G/A?

The filing lists Rosalind Advisors, Inc., Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P., Steven Salamon, and Gilad Aharon as reporting persons. Rosalind Advisors acts as investment advisor to the funds, with Salamon and Aharon serving as portfolio managers associated with the advisor.

How many InspireMD (NSPR) warrants do the Rosalind investors hold?

The group references 7,081,361 InspireMD common shares issuable upon exercise of pre-funded and standard warrants. These potential shares are subject to a 9.99% blocker, which currently prevents warrant exercises that would push their beneficial ownership above that threshold.

What is the blocker provision affecting InspireMD (NSPR) warrants held by Rosalind?

The warrants contain a 9.99% “blocker” limiting how many shares can be acquired upon exercise. The holders cannot exercise any warrants if doing so would result in beneficial ownership above 9.99% of InspireMD’s outstanding common stock, effectively capping their exercisable position.

Are the Rosalind investors seeking control of InspireMD (NSPR) with this stake?

The reporting persons state the securities were acquired and are held in the ordinary course of business. They certify that the holdings are not for the purpose of changing or influencing control of InspireMD and are not part of any control-related transaction.

How is beneficial ownership in InspireMD (NSPR) allocated among the Rosalind funds?

Rosalind Master Fund L.P. reports 8.3% of the class and Rosalind Opportunities Fund I L.P. reports 1.0%. Rosalind Advisors, Inc., and portfolio managers Steven Salamon and Gilad Aharon may be deemed to share beneficial ownership through their advisory and management roles.
Inspiremd

NASDAQ:NSPR

NSPR Rankings

NSPR Latest News

NSPR Latest SEC Filings

NSPR Stock Data

74.15M
18.66M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MIAMI